Cite
MLA Citation
David Malka et al.. “FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.” European journal of cancer, vol. 115, 2019, pp. 97–106. http://access.bl.uk/ark:/81055/vdc_100086215718.0x000037